base metals investing Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
base metals investing Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
base metals investing Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
base metals investing Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
base metals investing Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
base metals investing Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
base metals investing Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
base metals investing Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
base metals investing Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
base metals investing Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
base metals investing Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
base metals investing Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
